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Epicardially implanted Dsotalol polyurethane composite matrices for preventing ischemic ventric- 
ular arrhythmias were studied in open chest dogs under general anesthesia. D-sotalol was combined 
with a polyureapolyurethane (3:7) in solvent-cast films, which were characterized in vitro for their 
drug release at 37°C at pH 7.4 (0.05 M K2HP04). D-sotalol in vitro release occurred rapidly in an 
initial burst phase, with roughly 20% released within the first five min, and 90% by 60 min. Thereafter, 
an exponentially decreasing release rate was observed with matrix depletion by live hours. In the ani- 
mal studies, the left anterior descending coronary artery (LAD) was occluded for 10 min on an hourly 
basis for up to live occlusions. 10 min prior to the third LAD occlusion, either a D-sotalol matrix or a 
vehicle matrix (control) was placed on either the ischemic or nonischemic left ventricular epicardium. 
The study was then continued observing the effects of matrix placement on occlusions 3,4, and 5.200 
mg D-SOtdO matrices, which delivered a net dose of 1.2 mg/kg, effectively inhibited ventricular ar- 
rhythmias only if placed on the left ventricular ischemic zone. Placement of 200 mg D-sotalol matrices 
in the nonischemic zone was ineffective for significantly reducing the occurrence of ventricular ar- 
rhythmias. Furthermore, D-sotalol controlled release matrices were ineffective for preventing ventric- 
ular fibrillation (VF) regardless of dose or placement site. 200 mg ischemic zone D-sotalol matrices 
resulted in plasma sotalol levels in regional coronary venous samples ranging from 3.5 pg/ml to 10.4 
&ml. However, peripheral sotalol levels obtained simultaneously ranged from 0.23 pg/ml to 0.78 ,ug/ 
ml. It is concluded that epicardial D-sotalol controlled release matrices inhibited ischemic ventricular 
arrhythmias, but not VF, if placed in the left ventricular ischemic zone during repeated LAD occlusions. 
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Introduction 
Therapy for ventricular arrhythmias is limited 
by a variety of factors including cardiac and non- 
cardiac side effects. Previous research from our 
laboratory has demonstrated that drug-polymer 
composites, known as controlled release matri- 
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of animal models [ l-6 1. For example, dogs with 
ouabain induced ventricular tachycardia were 
successfully converted to sinus rhythm with li- 
docaine-polyurethane controlled release matri- 
ces placed on the left ventricular epicardium [ l- 
3 ]. Furthermore, ventricular tachycardia in- 
duced by rapid ventricular pacing was also suc- 
cessfully converted to sinus rhythm in an open 
chest dog model with placement of lidocaine-po- 
lyurethane matrices on the left ventricular epi- 
cardium [ 45 1. 
Ischemia-induced ventricular tachycardia in 
dogs during hourly 10 min, complete occlusions 
of the left anterior descending coronary artery 
(LAD) was similarly significantly inhibited due 
to the placement of verapamil-polyurethane 
controlled release matrices on either the is- 
chemic or nonischemic regions of the left ven- 
tricular epicardium [ 61. In addition, related ex- 
periments also demonstrated that epicardial 
antiarrhythmic drug matrices were not associ- 
ated with any drug-related cardiac or systemic 
side effects [ 5,6 1. 
Recent clinical and laboratory research has 
emphasized the importance of Class III antiar- 
rhythmia agents for the therapy of ventricular 
arrhythmias. Sotalol is an interesting compound 
in this regard, since the 1-stereoisomer has both 
beta-adrenergic blocking effects and Class III an- 
tiarrhythmic activity [ 7,8], whereas the D-ster- 
eoisomer has been reported to have predomi- 
nantly Class III antiarrhythmic activity and is 
almost devoid of &blocking effects [ 9,lO 1. For 
this reason, D-sotalol was chosen for use as a 
model Class III compound in these further in- 
vestigations of controlled release implants for 
ventricular arrhythmias due to acute coronary 
ischemia. The goals of the present study were to: 
( 1) formulate and characterize D-sotalol-polyu- 
rethane controlled release matrices in terms of 
their in vitro drug release; (2 ) assess the efficacy 
of D-sotalol controlled release matrices for inhib- 
iting ischemia-induced ventricular arrhythmias 
occurring as a result of repeated acute LAD oc- 
clusions in a canine model; and (3) determine 
the myocardial and plasma disposition of D-SO- 
talol administration by epicardial matrices. 
~eth~s 
Materials 
D-sotalolHC1 (MJ-5763-1-D) and the inter- 
nal standard (MJ-6564-1) were obtained from 
Bristol Meyers Squibb, Inc. (Wallingford, CT). 
Methane sulfonic acid, N,N-dimethyl acetamide 
and 1 -heptane sulfonic acid were purchased from 
Aldrich Chemical Company (Milwaukee, WI), 
and N,i%bis (2-hydroxyethyl )-~ycine and pro- 
cainamide hydrochloride were obtained from 
Sigma Chemical, Inc. (St. Louis, MO). Chloro- 
form (Mdlinckrodt, St. Louis, MO), methanol 
(Mallinckrodt ) and isoamyl alcohol (J.D. Baker, 
Phillipsburg, NJ) were all high performance liq- 
uid chromatography grade. Acetic acid, sulfuric 
acid, sodium hydroxide, sodium chloride, potas- 
sium phosphate-dibasic, and potassium phos- 
phate monobasic were all retained at reagent 
grade purity (Mallinc~odt, Paris, KY ). 
Controlled release matrix formulation and 
characterization 
Mitralthane MPUS (Polymedica, Inc., Whea- 
tridge, CO) was dissolved in dimethyl aceta- 
mide as a 25% solution. D-sotalol was codis- 
solved in the dimethyl a&amide-MPUS solution 
in proportions adjusted to give a final composi- 
tion of 30% D-sotalol and 70% MPUS. Matrices 
were then solvent cast in teflon coated molds, and 
oven dried under vacuum at 50°C. Solvent free 
matrices were 600 microns in thickness. 
Individual slab matrices were incubated in 5 
ml sample volumes of 0.05 M K2HP04(pH 7.4) 
at 37 ‘C on an orbit shaker ( 110 rpm) under per- 
fect sink conditions. The buffer was replenished 
on a regular basis and samples were periodically 
analyzed to monitor in vitro drug release. Sotalol 
concentration was determined either by absor- 
bance at a wavelength of 227 nm using a Perkin 
Elmer Lambda 3B spe~trophotometer (Nor- 
walk, CT), or by high performance liquid chro- 
matography (see below ), 
Animal model preparation 
Each experiment utilized an open-chest dog 
preparation [ 61 subjected to hourly complete 
occlusions of the left anterior descending coro- 
nary artery (LAD) for 10 min followed by reper- 
fusion. The use of animals conformed to the 
“position of the American Heart Association on 
Research Animal Use”, adopted Nov. 11, 1984. 
Five LAD occlusions were carried out with each 
animal with polyurethane matrix placement 
(drug or vehicle) prior to the third occlusion as 
described below. Thirty five male mongrel dogs 
(20 to 30 kg weight range) were used in these 
experiments. Animals were anesthetized with 
sodium pentobarbital, and the right femoral ar- 
tery catheter was placed for monitoring blood 
pressure continuously during the studies. In ad- 
dition, a right femoral venous catheter was also 
inserted for blood sampling. A left thoracotomy 
was then performed, and a pericardial cradle cre- 
ated. The left anterior descending coronary ar- 
tery (LAD) was isolated and dissected proximal 
to its first branch. A snare consisting of a 2-O silk 
ligature was placed around the LAD for periodic 
occlusions. Obvious left ventricular collateral 
branches communicating with the LAD distri- 
bution were tied off with 3-O silk sutures. Uni- 
polar epicardial platinum electrodes were placed 
in the ischemic zone and nonischemic zone of the 
left ventricle, and a bipolar epicardial platinum 
electrode was sewn in place onto the left atrial 
appendage for atria1 pacing. In addition, all ani- 
mals were configured with standard surface elec- 
trocardiogram electrodes and lead II was typi- 
cally recorded. All data were continuously 
recorded on a Hewlett Packard Model PDR HP 
8 channel FM open reel tape recorder (Hewlett- 
Packard, Andover, MA). Recorded data was also 
displayed on line using a Codas analogue to dig- 
ital conversion system (DATA Q, Akron, OH). 
LAD occlusion and drug protocols 
Two matrix sizes were used in the animal 
studies, either 200 mg or 100 mg net weight per 
matrix. Each D-sotalolMPU5 matrix (30% D- 
sotalol) or vehicle (control) matrix was sewn 
into place with epicardial sutures (3-O vicryl) 10 
min prior to the third LAD occlusion. Following 
this, the third occlusion was carried out on 
schedule, as well as fourth and fifth occlusion 
with a one hour interval between each occlusion. 
Once drug matrices were placed, heparinized 
blood samples were periodically removed from a 
coronary vein proximal to the drug matrix and 
simultaneously from the right femoral vein. At 
the conclusion of the study, animals were eu- 
thanized with an overdose of pentobarbital fol- 
lowed by injection of concentrated potassium 
chloride. After this, full thickness samples of 
myocardium from directly beneath the drug ma- 
trix, and 2 cm distal from it, were taken for sub- 
sequent sotalol analyses (see below). Further- 
more, each Dsotalol matrix was stored frozen for 
subsequent analysis of residual drug. 
Animals which failed to develop ventricular 
tachycardia during the first LAD occlusion were 
used for in vivo matrix release investigations. In 
these experiments, seven 10.0 mg matrix sam- 
ples were placed on the left ventricular epicar- 
dial surface along the LAD distribution distal to 
the occluder. Matrix samples were removed at 
intervals of 15, 30, 45, 60, 90, 120 and 130 min 
and were stored frozen for subsequent D-sotalol 
extraction and analysis by HPLC (see below). 
Ventricular arrhythmia analyses 
Animals were continuously paced during these 
studies (cycle length, 330 ms) via the left atrial 
electrodes using a Grass Model 2000 Stimulator 
(Grass Instruments, Quincy, MA) set at twice 
diastolic capture thresholds. The following ven- 
tricular arrhythmias were noted during acute oc- 
clusions: isolated ventricular premature beats 
were recorded and quantitated, as were couplets. 
Episodes of nonsustained ventricular tachycar- 
dia, defined as three or more consecutive pre- 
mature ventricular beats, were also noted and 
quantitated. Animals developing ventricular fi- 
brillation (VF) during acute LAD occlusions, 
were assessed as to the duration of the occlusion 
until VF occurred. In addition, the occurrence of 
ventricular fibrillation during reperfusion was 
also noted. Animals with VF were promptly elec- 
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t&ally defibrillated, and the study continued. 
Ventricular arrhythmia data were compared 
between control and individual treated groups 
using unpaired t-test for each individual occlu- 
sion. This was necessary since repeated LAD oc- 
clusions lead to myocardial stunning [ 111 and 
other accumulative effects which thereby ob- 
viate comparing successive occlusions to each 
other within an experimental group. Ventricular 
fibrillation episodes, either during ischemia or 
during reperfusion, were similarly compared for 
each occlusion interval, control versus individ- 
ual treatment group, for each of the various 
treatment regimes. Statistical significance was 
assessed for the occurrence of VF with chi square 
testing. 
D-Sotalol extraction procedures and HPLC 
analyses 
D-Sotalol in the plasma samples was quanti- 
tied by HPLC using an ultraviolet detector, 
whereas myocardial samples were assayed using 
a fluorescence detector. MJ-6564-1 was used as 
an internal standard for plasma and matrix anal- 
yses and procainamide hydrochloride for my- 
ocardial samples. Stock solutions of D-sotalol 
hydrochloride and the internal standards were 
prepared in distilled water and were stored at 
4°C. The buffer solution was prepared from a 
saturated solution of N,N-bis (2-hydroxyethyl)- 
glycine in distilled water, filtered and adjusted to 
pH 9.0 with 10 M sodium hydroxide [ 12,13 1. 
Each 1 ml plasma sample was first spiked with 
100 ~1 of internal standard and 200 fl of buffer 
solution (pH 9.0), and then extracted with 8 ml 
extracting solvent consisting of a mixture of 
chloroform and isoamyl alcohol (3: 1 v/v). The 
organic layer (5 ml) was removed through the 
lower phase and then mixed with 300 ~1 of 0.05 
M sulfuric acid. An aliquot of the upper layer 
( 100 ~1) was then injected into the reversed- 
phase column. 
Myocardial samples for sotalol analyses were 
first grossly stratified into epicardial, midmy- 
ocardial, and endocardial layers. Stratified sam- 
ples (0.5 g) were homogenized with 2.2 ml 0.9% 
NaCl and then treated in the same way as plasma 
samples except that procainamide hydrochlo- 
ride was used as an internal standard. Matrix 
samples for assessment of residual D-sotalol con- 
tent were extracted in refluxing methanol using 
a Soxhlet apparatus. Methanol extracts were 
evaporated to dryness and redissolved in 0.05 M 
sulfuric acid for HPLC analyses using MJ-6564- 
1 as an internal standard. 
Dsotalol separations were carried out using a 
Waters (Milford, MA) HPLC system consisting 
of an HPLC pump (Model 501), a WISP 712 
autosampler, a 30 cmx 3.9 mm (internal diam- 
eter) reversed-phase p-Bondpack C1 8 ( 10~ par- 
ticle size) with a IUSS Guard-pak precolumn 
insert with 10~ particles, a variable wavelength 
U.V. detector, Model 48 1, set at 235 nm., a scan- 
ning fluorescence detector, Model 470, set at ex- 
citation wavelength 235 and emission wave- 
length at 320 nm, and a Data Module 740 
recorder. 
The mobile phase [ 12,13 ] for plasma and ma- 
trix analyses was water-methanol-acetic acid- 
methanesulfonic acid (91:8.5:0.5:0.025 v/v). 
The mixture was adjusted to pH 3.3 with 10 M 
sodium hydroxide, filtered through a 0.45 pm 
filter and vacuum degassed before use. The chro- 
matography flow rate was 1.5 ml/min, which 
produced a pressure 1500 psi. However, the mo- 
bile phase for myocardial sample analyses was 
methanol-acetic acid-water (35: 1:64 v/v) with 
0.005 M w/v 1-heptane sulfonic acid [ 12- 141. 
It was also filtered through a 0.45 pm filter and 
vacuum degassed before use. The HPLC flow rate 
was also 1.5 ml, which resulted in a pressure of 
3300 psi. 
All separations were made at ambient temper- 
ature, and peak areas were reported. Five work- 
ing standard plasma (or tissue) samples were 
prepared from appropriate dilutions of stock so- 
lutions of D-sotalol hydrochloride to give con- 
centrations ranging from 0 to 4000 ng/ml (0 to 
10 000 rig/g for myocardial tissue). Calibration 
curves were constructed by plotting sotalol/in- 
temal standard peak area ratios from the ex- 
tracted samples versus the sample sotalol con- 
centration. The statistical significance of the 
differences between groups of plasma level sam- 
ples, or myocardial samples was assessed using 
unpaired t-tests. 
Results 
~Sotalol release in vitro occurred rapidly, with 
an initial burst phase of roughly 20% of incor- 
porated drug within the first 5 min (Fig. ! ). Fur- 
thermore, by 60 min about 90% of the cumula- 
tive release had occurred. Thereafter, an 
exponentially decreasing release rate was ob- 
served with nearly complete matrix depletion 
after 5 hours of in vitro release. Five dogs were 
excluded from the a~h~hmia efficacy study 
0 20 40 60 80 100 120 140 160 
Minutes 
Fig. 1. In vitro (triplicate samples) compared to in vivo 
(N=S) release of Dsotalol from polyurethane matrices, 
shown as percentage of cumulative release. 
TABLE 1 
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(below) because of the absence of VT during the 
first occlusion; however, these animals were uti- 
lized for in vivo matrix release experiments (as 
above). The in vivo sotalol release pattern was 
comparable to that observed in vitro, except that 
the release rate was roughly one half of that noted 
in vitro (Fig. 1). 
Prior to matrix placement LAD occlusions re- 
sulted in multifo~ unstable ventricular ectopy 
with progressive severity during the course of 
each 10 min occlusion. Nonsustained VT typi- 
cally occurred for 3 to 15 consecutive beats in 
control occlusions (prior to matrix placement, 1 
and 2) and vehicle occlusions (3,4,5, nondrug 
matrices). In all studies in which nonsustained 
ventricular tachycardia (VT) was induced dur- 
ing the first occlusion, it recurred at a compara- 
ble frequency (Table 1 ), during the second oc- 
clusion, and for the remaining vehicle studies 
during occlusions 3-5 as well. 
The occurrences of isolated premature beats 
and couplets are presented in Table 2 and Table 
3. Couplets occurred at a rate of 1.24-2.29/min 
in both D-sotalol (pretreatment ) and vehicle an- 
imals during the first occlusions (Table 2). In 
addition isolated premature beats also occurred 
frequently during nontreatment occlusions as 
well (Table 3 ). Ventricular fibrillation occurred 
after 5.1-7.3 min in 57% to 85% of animals in 
the various groups during the first occlusions 
(Table 4). Furthermore, ventricular fibrillation 
occurred during reflow in all untreated dogs not 
fibrillating during the LAD occlusion, and thus, 
undergoing reperfusion after 10 min of acute is- 
Inhibition of isolated ventricular premature beats with D-sotalol matrices (episodes/min) 
Group N Occlusion 
(matrix wt) 
I II III IV V 
Control (vehicle) 9 3.85 + 1.03 3.01 f 0.65 2.43 It 0.97 2.75kO.98 2.17i.O.67 
200 mg 12 7 5.07& 1.50 1.47f0.47 1.1820.39 0.63 f 0.20* 0.37+0.17** 
200 NIZ mg 7 3.8lk2.11 5.33 f 2.49 1.59kO.48 2.45 k 0.99 0.74 + 0.43 
1OOmgIZ 7 3.14k2.00 1.61 kO.53 1.07kO.37 1.39kO.71 1.52kO.23 
IZ= ischemic zone matrix placement, 3rd occlusion; NIZ= nonischemic zone matrix placement, 3rd occlusion; *p=O.O5 1, 
wt=2.11, treated vs. control; **p=O.O3, k2.36, treated vs. control. 
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TABLE 2 
Inhibition of coupiets with D-sotalol matrices (episodes/min) 
Group N Occlusion* 
(matrix wt. ) 
I II III IV V 
Control (vehicle) 9 1.37kO.53 0.51 kO.17 0.68kO.21 0.47+0.15 0.57+0.21 
200 mg 7 2.29 k 0.98 0.41 f0.13 0.57~0.17 0.14~0.09 0.15+0.05 
200 mg NIZ 7 1.24f0.68 1.73f0.78 0.61 f0.20 0.79 k 0.42 0.32kO.30 
1OOmgIZ 7 1.37fO.14 0.55f0.42 0.48f0.19 0,49 k 0.38 0.50+0.14 
IZ=ischemic zone matrix placement, 3rd occlusion; NIZ=nonischemic zone matrix placement, 3rd occlusion; *p>O.OS for 
control vs. treated for all occlusions. 
TABLE 3 




I II III IV V 
Control (vehicle) 9 1.25kO.27 1.18kO.41 0.74kO.22 1.53f0.74 1.02iO.36 
200 mg IZ 7 1.48kO.44 0.75f0.28 0.84f0.16 0.57f0.16 0.33+0.125 
200 mg NIZ 7 1.42kO.53 1.50f0.60 1.28f0.29 1.28f0.52 0.88f0.41 
1OOmgIZ 7 1.02kO.38 0.96 + 0.42 0.43kO.13 0.84 f 0.25 0.93f0.34 
IZ=ischemic zone matrix placement, 3rd occlusion; NIZ=nonischemic zone matrix placement, 3rd occlusion; *p>O.O5 for 
contro1 vs. treated for all occlusions. 
TABLE 4 
Effects of epicardial D-SOtal on ventricular fibrillation 
Group N 1st Occlusion (pre drug) 5th Occlusion (2 h of drug) 
Ischemic VF Time to Reperfusion Ischemic VF Time to Reperfusion 
ischemic VF VF ischemic VF 
(min) (min) 
200 IZ mg 7 4/7 (57.1%) 6.5f 1.2 3/3 (100%) 6/7 (85.1%) 6.2+ 1.1 l/l (100%) 
200 NIZ mg 7 4/7 (57.1%) 7.320.9 3/3 (100%) 717 (100%) 5.9k0.6 O/O (0%) 
IOOmgIZ 7 6/7 (85.7%) 5.1 f 1.0 l/l (100%) 3/6 (50%) 6.8? 1.2 3f3 (100%) 
Vehicle (control) 9 7/9 (77.7%) 5.7i 1.0 2/2 (100%) 8/9 (888%) 5.4kO.8 l/l (100%) 
chemia. Isolated premature beats were signifi- 
cantly reduced in the 200 mg matrix ischemic 
zone placement studies (Table 1). A similar 
trend, although not statistically significant was 
noted for couplets in the 200 mg matrix ischemic 
zone results, and with both the 200 mg matrix 
nonischemic zone studies and the 100 mg sotalol 
matrices when placed in the ischemic zone (Ta- 
ble 2). However, none of the matrices were ef- 
fective for signi~c~tly inhibiting isolated pre- 
mature beats or couplets when placed in the 
nonischemic zone. 
D-sotalol-MPUS matrices were effective for 
inhibiting ventricular tachycardia during acute 
4 EPI (PROX) r- q MID (PROX) fd ENDO (PROX) q EPI (DIST) 
nglml 
W 
Fig. 2. Plasma sotalol levels comparing peripheral sotalol to 
coronary venous concentrations in animals (N= 7) receiving 
200 mg D-SOtakOl controlled release matrices placed prior to 
the 3rd of 5, 10 min LAD occlusions (hourly), on the is- 
chemic zone (A) of the Ieft ventricular epicardium in open 
chest dogs, compared to 200 mg matrix nonischmic zone 
studies (B), and 100 mg matrix ischemic zone experiments 
(C). 
ischemia; however, these results were not statis- 
tically significant for any of the drug systems in- 
cluding the 200 mg matrices placed in the is- 
chemic zone (Table 1). As shown in Table 3, 
beginning with the third occlusion, there was a 
progressive decrease in the incidence of VT, 
200 12 200 NIZ 
GROUP 
100 IZ 
Fig. 3. Myocardial sotalol concentration in stratified sam- 
ples, from animals receiving 200 mg or 100 mg controlled 
release matrices placed on either the left ventricular ischemic 
zone (IZ) or nonischemic zone (NIZ) (200 mg only), of the 
epicardium in animals undergoing repeated 10 min complete 
occlusions (hourly) of the left anterior descending coronary 
artery (LAD). Proximal (PROX) and distal (DIST) sam- 
ples compared levels in myocardial strata including epicar- 
dium (EPI), midmyocardium (MID), and endocardium 
(END). 
which declined to the lowest levels by the time of 
the fifth LAD occlusion for the 200 mg ischemic 
zone matrix placement studies. When 200 mg 
matrices were placed in the nonischemic zone, 
no trend in reducing VT was observed. Simi- 
larly, 100 mg matrices placed in either the is- 
chemic or nonischemic zones were also not sig- 
nificantly effective compared to controls (Table 
3). 
By the 5th LAD occlusion ventricular fibrilla- 
tion occurred after 6.2 ? 1.1 min. in 85.7% of dogs 
treated with 200 mg D-sotalol controlled release 
matrices placed in the ischemic zone (Table 4); 
200 mg nonischemic zone matrices were simi- 
larly ineffective (Table 4). These data did not 
differ significantly from control. Ischemic zone 
placements of 100 mg matrices were also ineffec- 
tive for ventricular fibrillation (Table 4). Fur- 
thermore, reperfusion ventricular fibrillation oc- 
curred in all animals not fibrillating during acute 
ischemia, regardless of D-sotalol controlled re- 
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lease therapy. Thus, controlled release D-sotalol 
therapy, although effective for ischemia-induced 
ventricular arrhythmias, was ineffective for VF 
induced by either ischemia or reperfusion. 
Matrix retrieval analyses demonstrated that the 
200 mg D-sotalol ischemic zone matrices deliv- 
ered a mean net dose of 1.2 mg/kg. D-sotalol pe- 
ripheral plasma levels in the 200 mg ischemic 
zone studies ranged from 0.23 pg/ml to 0.78 ,ug/ 
ml; however, simultaneous coronary venous lev- 
els were much higher, ranging from 3.53 pg/ml 
to 10.44 pg/ml (Fig. 2). Despite the lack of sta- 
tistically significant efficacy for ventricular ar- 
rhythmias of the nonischemic zone matrices, or 
the 100 mg matrices regardless of placement site, 
these controlled release administrations also re- 
sulted in comparable plasma levels to those noted 
with the efficacious 200 mg ischemic zone matri- 
ces. For example, 200 mg nonischemic zone D- 
sotalol matrix placement resulted in coronary 
venous levels ranging from 1.54 lug/ml to 3.64 
lug/ml, with 0.20 ,ug/ml to 0.99 pg/ml peripher- 
ally by comparison (Fig. 2). Furthermore, 100 
mg ischemic zone matrix implants resulted in 
coronary plasma levels ranging from 1.45 pg/ml 
to 7.95 pg/ml and peripheral plasma sotalol lev- 
els ranging from 0.13 /g/ml to 0.30 ,ug/ml (Fig. 
2). 
Myocardial sotalol levels in the 200 mg is- 
chemic zone studies were highest in the proximal 
epicardium, and next highest in the proximal 
midmyocardium and the endocardium; proxi- 
mal mid- and endocardial sotalol levels were 
comparable (Fig. 3). However, distal sotalol 
levels in the 200 mg ischemic zone studies were 
significantly lower than proximal endocardial 
levels, indicating a relatively rapid gradient dis- 
tribution of D-sotalol to distal myocardial re- 
gions. Although 200 mg nonischemic zone so- 
talol matrix placements demonstrated a proximal 
to distal drug distribution comparable to is- 
chemic zone placement, total sotalol levels were 
lower in the nonischemic zone matrix studies 
compared to the ischemic zone studies (Fig. 3). 
Similarly, 100 mg matrices placed in the is- 
chemic zone showed a comparable drug distri- 
bution pattern to the 200 mg matrices, but with 
lower sotalol tissue levels (Fig. 3 ). 
Discussion 
The present studies have demonstrated the 
class III antiarrhythmic agent, D-sotalol, incor- 
porated into polyurethane controlled release ma- 
trices was effective for preventing ventricular ar- 
rhythmias induced by acute ischemia. The acute 
ischemia animal model [ 6 ] used employing re- 
peated LAD occlusions mimics the pathophys- 
iology of an acute coronary obstruction, with as- 
sociated potentially fatal ventricular arrhythmias. 
Animal models of acute-ischemic ventricular ar- 
rhythmias [ 6,15 ] have not been widely used due 
to difficulties in assessing the typically nonsus- 
tained ventricular ectopy observed. However, our 
prior studies with controlled release verapamil 
[ 6 ] established the reliability of the present 
model system for investigating this clinically rel- 
evant setting. 
Among the determinants of controlled release 
D-sotalol efficacy were ischemic zone matrix 
placement, as well as the use of 200 mg matrices, 
which provided coronary venous sotalol levels in 
the same range as therapeutic peripheral levels 
observed clinically [ 16- 18 1. Also of significance 
is the fact that peripheral plasma levels in the 200 
mg ischemic zone studies were well below those 
known to be clinically effective [ 16- 18 1, and this 
result implies that the pharmacologic effects of 
D-sotalol administered to the epicardium were 
achieved locally. 
It is of interest, however, that despite signifi- 
cant differences in efficacy between 100 mg and 
200 mg sotalol matrices depending upon the site 
of placement, comparable coronary and periph- 
eral plasma levels were obtained in the ischemic 
zone placement studies for both the 100 mg and 
200 mg matrices. Thus, although coronary 
plasma concentration was enhanced with epicar- 
dial controlled release, the absolute drug levels 
achieved did not predict efficacy in the ischemic 
zone studies. However, the 200 mg nonischemic 
zone matrix placement results demonstrated 
coronary venous plasma levels which were al- 
most half those observed in the ischemic zone 
experiments. 
Myocardial concentrations may be a better in- 
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dication of therapeutic effectiveness, since en- 
hanced proximal myocardial sotalol levels were 
noted with 200 mg ischemic zone matrix place- 
ment. It may be that the drug retention is fa- 
vored in a myocardial region with an impaired 
regional circulation, such as the repeatedly is- 
chemic myocardium in the present experiments. 
Research by others has demonstrated enhanced 
myocardial drug levels of lidocaine [ 19,201 and 
propranolol [ 2 1,221 in infarcted tissue com- 
pared to normally perfused myocardium. Thus, 
inadequate perfusion of a myocardial region may 
in fact favor drug retention, and therefore work 
to the advantage of direct cardiac administra- 
tion of antiarrhythmic agents. Alternatively, 
since sotalol is a zwitterion with a relatively nar- 
row pH range in which charge dependent uptake 
variability may arise, minute pH differences 
within the ischemic zone due to cellular damage 
[23,24] may also serve to partition the drug 
within this region, inhibiting diffusion into the 
circulation. 
It is further of interest that controlled release 
D-sotalol therapy in the present studies did not 
favorably affect the occurrence of ventricular fi- 
brillation during either acute ischemia or reper- 
fusion. Prior work by our group using the same 
animal model with the calcium channel blocker, 
verapamil, incorporated into control release ma- 
trices, demonstrated a significant reduction in VF 
occurring during acute ischemia, but not reper- 
fusion [ 61. It is noteworthy that D-sotalol in the 
present study, and verapamil in our previous 
work were effective for preventing ventricular 
arrhythmias associated with acute ischemia. 
However, verapamil effectively inhibited VT and 
VF regardless of the site of matrix placement, 
while sotalol only significantly inhibited isolated 
ventricular ectopy if matrices were placed in the 
ischemic zone. Other agents such as the class I 
agent, lidocaine [ 25 1, or the beta adrenergic 
blocker propranolol [ 261 were not significantly 
effective in this acute-ischemia model system. 
Thus, fundamental mechanistic differences in 
drug action may also determine specific arrhyth- 
mia outcomes, rather than simply achieving in- 
tensely high regional concentration of an antiar- 
rhythmic agent in a nonspecific fashion. 
Although intravenous D-sotalol comparisons 
were not within the scope of the present re- 
search, the results of others have demonstrated 
that D-sotalol is an effective antiarrhythmic agent 
when administered intravenously. Nevertheless, 
the dosages (8 to 10 mg/kg) used in these pre- 
vious investigations ( 7- 10,16- 18 ), and the re- 
sulting peripheral plasma levels (peak level, 
50 000 ng/ml) (7-l 0,16- 18 ), were significantly 
higher than those reported in the present study. 
However, the coronary venous D-sotalol levels in 
the present study were comparable to therapeu- 
tic levels reported by others ( 7- 10,16- 19 ) . Fur- 
thermore, Lynch et al, [ 271 demonstrated that 
in a multiple dose (8 mg/kg intravenously every 
8 hours) pretreatment regimen, Dsotolal sup- 
pressed the induction of ventricular tachycardia 
in an infarction model system, and also provided 
significant protection against the development of 
ventricular fibrillation in response to further 
acute ischemia in conscious post-infarction dogs. 
The net acute dose of D-sotalol in these studies, 
however was almost eight times greater than in 
the present studies. Furthermore, Lynch et al. 
[ 271 also demonstrated that the cumulative sur- 
vival rates of multiple dose D-SOtdO administra- 
tion gave enhanced protection which was supe- 
rior to single dose pretreatment. They 
hypothesized that the enhanced efficacy of the 
multiple dose regimen was the result of optimi- 
zation of drug plasma concentrations or cardiac 
tissue levels or both in the post infarction dogs. 
Furthermore, Brachmann et al. [28] have 
shown that the D-sotalol intravenous therapy re- 
sulted in an increased ventricular effective re- 
fractory period, and that this occurred to a greater 
extent in the infarct zone than in the normally 
perfused regions. The D-isomer of sotalol, also 
used in the present studies, was shown by this 
group [ 28 ] to be an effective antiarrhythmic and 
antitibrillatory agent in infarcted dogs previ- 
ously subjected to a permanent complete occlu- 
sion of the LAD. Thus, prior work by others has 
demonstrated efficacy of D-sotalol for ventricu- 
lar arrhythmias, although with suboptimal 
administration regimens compared to epicardial 
drug delivery. 
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The matrices used in the present studies were 
comparable to polyurethane controlled release 
matrices utilized in previous arrhythmia re- 
search by our group [ l-6 1. The rapid early drug 
release characteristics of these matrices favors 
obtaining rapidly effective levels of the agents of 
choice, which would be most desirable for pre- 
venting or treating acute arrhythmia activity. 
This could be most clinically relevant in an acute 
setting such as early in the clinical course of a 
myocardial infarction (with a catheter-matrix 
placement strategy), or postcardiac surgery (with 
epicardial matrices placed at closure). 
It is of further interest, that in vivo matrix re- 
lease studies using the D-sotalol matrices in the 
present work, demonstrated a release pattern that 
was similar to that noted in vitro, but with a re- 
lease rate that was roughly 50% of that noted in 
vitro. This has been observed previously by our 
group [ 5 ] in studies of lidocaine release from 
epicardial matrices, and is most likely due to the 
fact that in vivo, drug release occurs only at the 
epicardial contacting surface, rather than from 
all surfaces of the matrix as would take place with 
in vitro incubations. 
Controlled release matrices may be formu- 
lated with release profiles that can be extended 
for decades, as has been demonstrated using 
controlled release systems for prevention of car- 
diovascular calcification in animal model exper- 
iments of bioprosthetic heart valve calcification 
[29,30]. In addition, multiyear controlled re- 
lease is currently in clinical use with a steroid 
eluting cardiac pacing lead [ 3 11. In this drug de- 
livery system, the electrode tip contains a sili- 
cone rubber-dexamethasone drug delivery sys- 
tem which slowly releases dexamethasone into 
the implant site of a pacemaker electrode [ 27 1. 
This effectively prevents acute inflammatory re- 
action and chronic scar tissue buildup, which 
would otherwise adversely affect electrical pac- 
ing capture thresholds. Thus, for the prevention 
of ventricular arrhythmias in a long term setting, 
extended controlled release implants may be 
readily formulated and tailored to suit clinical 
needs. 
In conclusion, D-sotalol controlled release ma- 
trices used as epicardial implants in dogs 
undergoing repeated LAD occlusion were effec- 
tive for preventing ischemia-induced ventricular 
tachycardia, couplets, and isolated premature 
beats. However, epicardial sotalol was only ef- 
fective when 200 mg matrices were used as is- 
chemic zone implants. In addition, these matri- 
ces were not effective for preventing ischemia or 
reperfusion induced ventricular fibrillation. D- 
sotalol controlled release resulted in enhanced 
coronary plasma drug concentration compared to 
simultaneous peripheral plasma drug levels. My- 
ocardial drug concentrations were most en- 
hanced in the ischemic myocardium, although a 
relatively rapid distribution of D-sotaIo1 to distal 
sites was also observed. 
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